276 related articles for article (PubMed ID: 34359624)
1. Glycosylation: Rising Potential for Prostate Cancer Evaluation.
Kałuża A; Szczykutowicz J; Ferens-Sieczkowska M
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359624
[TBL] [Abstract][Full Text] [Related]
2. The role of glycans in the development and progression of prostate cancer.
Munkley J; Mills IG; Elliott DJ
Nat Rev Urol; 2016 Jun; 13(6):324-33. PubMed ID: 27091662
[TBL] [Abstract][Full Text] [Related]
3. Glycans as Biomarkers in Prostate Cancer.
Scott E; Munkley J
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30893936
[TBL] [Abstract][Full Text] [Related]
4. Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors.
Orozco-Moreno M; Visser EA; Hodgson K; Hipgrave Ederveen AL; Bastian K; Goode EA; Öztürk Ö; Pijnenborg JFA; Eerden N; Moons SJ; Rossing E; Wang N; de Haan N; Büll C; Boltje TJ; Munkley J
Glycobiology; 2023 Dec; 33(12):1155-1171. PubMed ID: 37847613
[TBL] [Abstract][Full Text] [Related]
5. Glycosylation Changes in Prostate Cancer Progression.
Butler W; Huang J
Front Oncol; 2021; 11():809170. PubMed ID: 35004332
[TBL] [Abstract][Full Text] [Related]
6. Glycosylation is a global target for androgen control in prostate cancer cells.
Munkley J
Endocr Relat Cancer; 2017 Mar; 24(3):R49-R64. PubMed ID: 28159857
[TBL] [Abstract][Full Text] [Related]
7. Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.
Ferdosi S; Rehder DS; Maranian P; Castle EP; Ho TH; Pass HI; Cramer DW; Anderson KS; Fu L; Cole DEC; Le T; Wu X; Borges CR
J Proteome Res; 2018 Jan; 17(1):543-558. PubMed ID: 29129073
[TBL] [Abstract][Full Text] [Related]
8. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia.
Saldova R; Fan Y; Fitzpatrick JM; Watson RW; Rudd PM
Glycobiology; 2011 Feb; 21(2):195-205. PubMed ID: 20861084
[TBL] [Abstract][Full Text] [Related]
9. Glycosylation characteristics of colorectal cancer.
Holst S; Wuhrer M; Rombouts Y
Adv Cancer Res; 2015; 126():203-56. PubMed ID: 25727149
[TBL] [Abstract][Full Text] [Related]
10. Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma.
Ho WL; Hsu WM; Huang MC; Kadomatsu K; Nakagawara A
J Hematol Oncol; 2016 Sep; 9(1):100. PubMed ID: 27686492
[TBL] [Abstract][Full Text] [Related]
11. Abnormal sialylation and fucosylation of saliva glycoproteins: Characteristics of lung cancer-specific biomarkers.
Gao Z; Xu M; Yue S; Shan H; Xia J; Jiang J; Yang S
Curr Res Pharmacol Drug Discov; 2022; 3():100079. PubMed ID: 35005612
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive N-glycome profiling of cultured human epithelial breast cells identifies unique secretome N-glycosylation signatures enabling tumorigenic subtype classification.
Lee LY; Thaysen-Andersen M; Baker MS; Packer NH; Hancock WS; Fanayan S
J Proteome Res; 2014 Nov; 13(11):4783-95. PubMed ID: 25210975
[TBL] [Abstract][Full Text] [Related]
13. Glycosylation products in prostate diseases.
Dos Santos Silva PM; Albuquerque PBS; de Oliveira WF; Coelho LCBB; Dos Santos Correia MT
Clin Chim Acta; 2019 Nov; 498():52-61. PubMed ID: 31400314
[TBL] [Abstract][Full Text] [Related]
14. Study of glycosylation of prostate-specific antigen secreted by cancer tissue-originated spheroids reveals new candidates for prostate cancer detection.
Ideo H; Kondo J; Nomura T; Nonomura N; Inoue M; Amano J
Sci Rep; 2020 Feb; 10(1):2708. PubMed ID: 32066783
[TBL] [Abstract][Full Text] [Related]
15. The glycosylation landscape of pancreatic cancer.
Munkley J
Oncol Lett; 2019 Mar; 17(3):2569-2575. PubMed ID: 30854032
[TBL] [Abstract][Full Text] [Related]
16. Glycosylation Changes in Brain Cancer.
Veillon L; Fakih C; Abou-El-Hassan H; Kobeissy F; Mechref Y
ACS Chem Neurosci; 2018 Jan; 9(1):51-72. PubMed ID: 28982002
[TBL] [Abstract][Full Text] [Related]
17. Site-specific and linkage analyses of fucosylated N-glycans on haptoglobin in sera of patients with various types of cancer: possible implication for the differential diagnosis of cancer.
Takahashi S; Sugiyama T; Shimomura M; Kamada Y; Fujita K; Nonomura N; Miyoshi E; Nakano M
Glycoconj J; 2016 Jun; 33(3):471-82. PubMed ID: 26869352
[TBL] [Abstract][Full Text] [Related]
18. The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer.
Hodgson K; Orozco-Moreno M; Scott E; Garnham R; Livermore K; Thomas H; Zhou Y; He J; Bermudez A; Garcia Marques FJ; Bastian K; Hysenaj G; Archer Goode E; Heer R; Pitteri S; Wang N; Elliott DJ; Munkley J
Sci Rep; 2023 Oct; 13(1):17031. PubMed ID: 37813880
[TBL] [Abstract][Full Text] [Related]
19. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects.
Fujimura T; Shinohara Y; Tissot B; Pang PC; Kurogochi M; Saito S; Arai Y; Sadilek M; Murayama K; Dell A; Nishimura S; Hakomori SI
Int J Cancer; 2008 Jan; 122(1):39-49. PubMed ID: 17803183
[TBL] [Abstract][Full Text] [Related]
20. In-depth N-glycome profiling of paired colorectal cancer and non-tumorigenic tissues reveals cancer-, stage- and EGFR-specific protein N-glycosylation.
Sethi MK; Kim H; Park CK; Baker MS; Paik YK; Packer NH; Hancock WS; Fanayan S; Thaysen-Andersen M
Glycobiology; 2015 Oct; 25(10):1064-78. PubMed ID: 26085185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
